Lupin Raises FY26 Margin Guidance to 27-28% Amid Strong Growth

• Lupin increased its FY26 margin guidance to 27-28% from 25-26%, driven by revenue growth and cost control.
• Ramesh S, CFO, expects margins to stabilize around 25% in FY27 despite potential R&D spending increases.
• CEO Vinita Gupta attributes US growth to exclusivity benefits from Tolvaptan and Mirabegron, and strong base generics.
• Lupin aims to exceed $1 billion in US sales by FY26 and sustain it into FY27 with injectables and biosimilars.
• Managing Director Nilesh Gupta announced the India launch of Semaglutide (SemaNext) in March, targeting ₹50 crore+ sales.